

IL10 Antibody (Center) Blocking Peptide
Synthetic peptide
Catalog # BP9112c**Specification****IL10 Antibody (Center) Blocking Peptide -
Product Information**Primary Accession [P22301](#)**IL10 Antibody (Center) Blocking Peptide -
Additional Information****Gene ID** 3586**Other Names**Interleukin-10, IL-10, Cytokine synthesis
inhibitory factor, CSIF, IL10**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP9112c](/products/AP9112c) was selected from the Center region of human IL10. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**IL10 Antibody (Center) Blocking Peptide - Protein
Information****Name** IL10**Function****IL10 Antibody (Center) Blocking Peptide -
Background**

The protein is a cytokine produced primarily by monocytes and to a lesser extent by lymphocytes. This cytokine has pleiotropic effects in immunoregulation and inflammation. It down-regulates the expression of Th1 cytokines, MHC class II Ags, and costimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production. This cytokine can block NF-kappa B activity, and is involved in the regulation of the JAK-STAT signaling pathway. Knockout studies in mice suggested the function of this cytokine as an essential immunoregulator in the intestinal tract.

**IL10 Antibody (Center) Blocking Peptide -
References**

Trajkov,D., et.al., Indian J Tuberc 56 (3), 117-131 (2009) Kim,J.M., et.al., J. Immunol. 148 (11), 3618-3623 (1992)

Major immune regulatory cytokine that acts on many cells of the immune system where it has profound anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Mechanistically, IL10 binds to its heterotetrameric receptor comprising IL10RA and IL10RB leading to JAK1 and STAT2-mediated phosphorylation of STAT3 (PubMed:<a href="http://www.uniprot.org/citations/16982608"

target="_blank">16982608). In turn, STAT3 translocates to the nucleus where it drives expression of anti-inflammatory mediators (PubMed:<a href="http://www.uniprot.org/citations/18025162"

target="_blank">18025162). Targets antigen-presenting cells (APCs) such as macrophages and monocytes and inhibits their release of pro- inflammatory cytokines including granulocyte-macrophage colony-stimulating factor /GM-CSF, granulocyte colony-stimulating factor/G- CSF, IL-1 alpha, IL-1 beta, IL-6, IL-8 and TNF-alpha (PubMed:<a href="http://www.uniprot.org/citations/1940799"

target="_blank">1940799, PubMed:<a href="http://www.uniprot.org/citations/7512027"

target="_blank">7512027, PubMed:<a href="http://www.uniprot.org/citations/11564774"

target="_blank">11564774). Interferes also with antigen presentation by reducing the expression of MHC-class II and co- stimulatory molecules, thereby inhibiting their ability to induce T cell activation (PubMed:<a href="http://www.uniprot.org/citations/8144879"

target="_blank">8144879). In addition, controls the inflammatory response of macrophages by reprogramming essential metabolic pathways including mTOR signaling (By similarity).

Cellular Location

Secreted.

Tissue Location

Produced by a variety of cell lines, including T- cells, macrophages, mast cells and other cell types

IL10 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)